| Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study SY Tartof, JM Slezak, H Fischer, V Hong, BK Ackerson, ON Ranasinghe, ... The Lancet 398 (10309), 1407-1416, 2021 | 1172 | 2021 |
| Obesity and mortality among patients diagnosed with COVID-19: results from an integrated health care organization SY Tartof, L Qian, V Hong, R Wei, RF Nadjafi, H Fischer, Z Li, SF Shaw, ... Annals of internal medicine 173 (10), 773-781, 2020 | 645 | 2020 |
| Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants HF Tseng, BK Ackerson, Y Luo, LS Sy, CA Talarico, Y Tian, KJ Bruxvoort, ... Nature medicine 28 (5), 1063-1071, 2022 | 494 | 2022 |
| Surveillance of autoimmune conditions following routine use of quadrivalent human papillomavirus vaccine C Chao, NP Klein, CM Velicer, LS Sy, JM Slezak, H Takhar, B Ackerson, ... Journal of internal medicine 271 (2), 193-203, 2012 | 270 | 2012 |
| Severe morbidity and mortality associated with respiratory syncytial virus versus influenza infection in hospitalized older adults B Ackerson, HF Tseng, LS Sy, Z Solano, J Slezak, Y Luo, CA Fischetti, ... Clinical Infectious Diseases 69 (2), 197-203, 2019 | 219 | 2019 |
| Effectiveness of mRNA-1273 against delta, mu, and other emerging variants of SARS-CoV-2: test negative case-control study KJ Bruxvoort, LS Sy, L Qian, BK Ackerson, Y Luo, GS Lee, Y Tian, ... Bmj 375, 2021 | 214 | 2021 |
| Safety of quadrivalent human papillomavirus vaccine administered routinely to females NP Klein, J Hansen, C Chao, C Velicer, M Emery, J Slezak, N Lewis, ... Archives of pediatrics & adolescent medicine 166 (12), 1140-1148, 2012 | 171 | 2012 |
| Observational safety study of febrile convulsion following first dose MMRV vaccination in a managed care setting SJ Jacobsen, BK Ackerson, LS Sy, TN Tran, TL Jones, JF Yao, F Xie, ... Vaccine 27 (34), 4656-4661, 2009 | 148 | 2009 |
| Durability of BNT162b2 vaccine against hospital and emergency department admissions due to the omicron and delta variants in a large health system in the USA: a test-negative … SY Tartof, JM Slezak, L Puzniak, V Hong, F Xie, BK Ackerson, SR Valluri, ... The Lancet Respiratory Medicine 10 (7), 689-699, 2022 | 124 | 2022 |
| Effectiveness of a third dose of BNT162b2 mRNA COVID-19 vaccine in a large US health system: a retrospective cohort study SY Tartof, JM Slezak, L Puzniak, V Hong, TB Frankland, BK Ackerson, ... The Lancet Regional Health–Americas 9, 2022 | 96 | 2022 |
| Real-world effectiveness of the mRNA-1273 vaccine against COVID-19: Interim results from a prospective observational cohort study KJ Bruxvoort, LS Sy, L Qian, BK Ackerson, Y Luo, GS Lee, Y Tian, ... The Lancet Regional Health–Americas 6, 2022 | 90 | 2022 |
| Pediatric vaccination during the COVID-19 pandemic BK Ackerson, LS Sy, SC Glenn, L Qian, CH Park, RJ Riewerts, ... Pediatrics 148 (1), 2021 | 88 | 2021 |
| The epidemiology of herpes zoster in immunocompetent, unvaccinated adults≥ 50 years old: incidence, complications, hospitalization, mortality, and recurrence HF Tseng, K Bruxvoort, B Ackerson, Y Luo, H Tanenbaum, Y Tian, ... The Journal of infectious diseases 222 (5), 798-806, 2020 | 76 | 2020 |
| Effectiveness and safety of an Haemophilus type b conjugate vaccine (PRP-T) in young infants CM Vadheim Pediatrics 92 (2), 271-279, 1993 | 71* | 1993 |
| Severe morbidity and short-and mid-to long-term mortality in older adults hospitalized with respiratory syncytial virus infection HF Tseng, LS Sy, B Ackerson, Z Solano, J Slezak, Y Luo, CA Fischetti, ... The Journal of Infectious Diseases 222 (8), 1298-1310, 2020 | 67 | 2020 |
| Hospitalization and emergency department encounters for COVID-19 after paxlovid treatment—California, December 2021–May 2022 DE Malden MMWR. Morbidity and mortality weekly report 71, 2022 | 65 | 2022 |
| Eradication of Haemophilus influenzae Type b Disease in Southern California CM Vadheim Arch Pediatr Adolesc Med 148 (1), 51-56, 1994 | 63* | 1994 |
| Rate and severity of suspected SARS-Cov-2 reinfection in a cohort of PCR-positive COVID-19 patients J Slezak, K Bruxvoort, H Fischer, B Broder, B Ackerson, S Tartof Clinical Microbiology and Infection 27 (12), 1860. e7-1860. e10, 2021 | 62 | 2021 |
| Effectiveness of mRNA-1273 vaccination against SARS-CoV-2 omicron subvariants BA. 1, BA. 2, BA. 2.12. 1, BA. 4, and BA. 5 HF Tseng, BK Ackerson, KJ Bruxvoort, LS Sy, JE Tubert, GS Lee, JH Ku, ... Nature Communications 14 (1), 189, 2023 | 59 | 2023 |
| BNT162b2 vaccine effectiveness against SARS-CoV-2 omicron BA. 4 and BA. 5 SY Tartof, JM Slezak, L Puzniak, V Hong, TB Frankland, BK Ackerson, ... The Lancet Infectious Diseases 22 (12), 1663-1665, 2022 | 53 | 2022 |
